Trial Profile
IVIG for Treatment of Resistant Neuropathic Pain: a Preliminary Study.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Neuropathic pain
- Focus Biomarker; Therapeutic Use
- 19 Sep 2012 Primary endpoint 'Pain-measures' has not been met.
- 31 Aug 2012 Results presented at the 14th World Congress on Pain.
- 25 Feb 2009 New trial record